Pharma News

The presence of a harmless bacterium found in the nose and on the skin may negatively impact the growth of a pathogen that commonly causes middle ear infections in children and pneumonia in children and older adults, says a new study.

Treatment with a hormone that plays an important role in labour and breast-feeding can improve behaviour of mothers suffering from postnatal depression, a common disorder affecting 10 to 20 percent of mothers, says a study.

LivaNova PLC received a Warning Letter dated December 29, 2015, from the United States Food and Drug Administration (“FDA”) alleging certain violations of FDA regulations applicable to medical device manufacturers at its Munich, Germany and Arvada, Colorado facilities.

MiMedx Group, Inc., the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced that it has recently posted an updated "Certificate to Foreign Government" on its website that describes all of the MiMedx  sheet form allografts and the Food and Drug Administration FDA's certification that the listed products are HCT/P's.

NeuroMetrix, Inc.  announced that it received a 510(k) clearance (K152954) from the U.S. Food and Drug Administration (FDA) for an upgraded version of Quell, the company's over-the-counter, 100% drug free chronic pain relief wearable. Under this 510(k), the Quell device can be controlled directly via the Quell Relief smartphone app. This provides an unprecedented level of convenience and comfort when using Quell to treat chronic pain.

Takeda Pharmaceutical Company Ltd.  and Enterome Bioscience SA (“Enterome”) announced they have entered into a strategic drug discovery collaboration to research and develop potential new therapeutics directed at microbiome targets thought to play crucial roles in gastrointestinal disorders, including inflammatory bowel diseases (e.g. ulcerative colitis) and motility disorders (e.g. irritable bowel syndrome).

[adsense:336x280:8701650588]

BOCA Cleartronic, Inc., through its subsidiary ReadyOp Communications, Inc., announces that the US Food and Drug Administration (FDA) has expanded its use of ReadyOp as an integral part of their communications and incident response planning.

The U.S. Food and Drug Administration announced new efforts to better understand how the agency can appropriately balance patient safety while encouraging advancements in hearing aid technology and access to these devices in the United States. The FDA will convene stakeholders for a public workshop and has re-opened a public comment period on a draft guidance related to the agency’s premarket requirements for hearing aids and personal sound amplification products (PSAPs).

Ionis Pharmaceuticals, Inc.  announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to IONIS-HTTRx for the treatment of patients with Huntington's disease (HD). IONIS-HTTRx is the first therapy to enter clinical development that is designed to directly target the cause of the disease by reducing the production of the protein responsible for HD. IONIS-HTTRx has also been granted orphan drug designation by the European Medicines Agency for the treatment of patients with HD.